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Long-term prognostic value of 13N-ammonia myocardial
perfusion positron emission tomography added value of coronary
flow reserve
Abstract
OBJECTIVES: The goal of this study was to assess the predictive value of myocardial perfusion
imaging with (13)N-ammonia positron emission tomography (PET) and coronary flow reserve (CFR) on
long-term prognosis in patients with suspected myocardial ischemia. BACKGROUND: No prognostic
data exist on the predictive value of CFR and (13)N-ammonia PET. METHODS: Perfusion and CFR
were assessed in 256 patients using (13)N-ammonia PET, and follow-up was obtained in 245 (96%)
patients. Sixteen early revascularized patients were excluded and 229 were assigned to normal versus
abnormal perfusion or normal versus abnormal CFR (<2.0). Major adverse cardiac events (MACE)
(cardiac death, nonfatal myocardial infarction, late revascularization, or hospitalization for cardiac
reasons) were assessed using the Kaplan-Meier method. Cox proportional hazard regression was used to
identify independent predictors for cardiac events. RESULTS: During follow-up (5.4 +/- 2.2 years), 78
patients had at least 1 cardiac event, including 29 cardiac deaths. Abnormal perfusion (n = 126) was
associated with a higher incidence of MACE (p < 0.001) and cardiac death (p < 0.05). In patients with
normal perfusion, abnormal CFR was independently associated with a higher annual event rate over 3
years compared with normal CFR for MACE (1.4% vs. 6.3%; p < 0.05) and cardiac death (0.5% vs.
3.1%; p < 0.05). In abnormal perfusion, CFR remained predictive throughout the 10-year follow-up (p <
0.001). CONCLUSIONS: Perfusion findings in (13)N-ammonia PET and CFR are strong outcome
predictors. CFR allows further risk stratification, suggesting a "warranty" period of 3 years if normal
CFR is associated with normal perfusion. Conversely, in patients with abnormal perfusion, an impaired
CFR has added value for predicting adverse outcomes.
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Structured Abstract 
Objectives: To assess the predictive value of myocardial perfusion imaging with 13N-
ammonia positron emission tomography (PET) and coronary flow reserve (CFR) on 
long-term prognosis in patients with suspected myocardial ischemia. 
Background: No prognostic data exist on predictive value of CFR and 13N-ammonia 
PET. 
Methods: Perfusion and CFR was assessed in 256 patients using 13N-ammonia PET 
and follow-up obtained in 245 (96%) patients. Sixteen early revascularized patients 
were excluded and 229 finally were assigned to normal versus abnormal perfusion or 
normal versus abnormal CFR (<2.0). Major adverse cardiac events (MACE; cardiac 
death, non-fatal myocardial infarction, late revascularization or hospitalization for 
cardiac reasons) were assessed using the Kaplan-Meier method. Cox proportional 
hazard regression was used to identify independent predictors for cardiac events. 
Results: During follow-up (5.4±2.2 years) 78 patients had at least one cardiac event 
including 29 cardiac deaths. Abnormal perfusion (n=126) was associated with a 
higher incidence of MACE (P<0.001) and cardiac death (P<0.05). In patients with 
normal perfusion abnormal CFR was independently associated with a higher annual 
event rate over 3 years compared to normal CFR for MACE (1.4% versus 6.3%; 
P<0.05) and cardiac death (0.5% versus 3.1%; P<0.05). In abnormal perfusion CFR 
remained predictive throughout the 10-year follow-up (P<0.001). 
Conclusions: Perfusion findings in 13N-ammonia PET and CFR are strong outcome 
predictors. CFR allows further risk stratification, suggesting a “warranty” period of 3 
years if normal CFR is associated with normal perfusion. Conversely, in patients with 
abnormal perfusion, an impaired CFR has added value for predicting adverse 
outcomes. 
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Condensed Abstract 
For prediction of long-term prognosis by 13N-ammonia positron emission tomography 
and coronary flow reserve (CFR) cardiac outcome was assessed in 229 patients 
during a mean follow-up of 5.4±2.2 years. Abnormal perfusion (n=126) was 
associated with a significantly higher incidence of cardiac events (P<0.001) and death 
(P<0.05). In patients with normal perfusion a normal CFR (≥2.0) was independently 
associated with a significantly lower annual event rate, suggesting a “warranty” period 
of 3 years, before disease onset. Conversely, in patients with abnormal perfusion, an 
impaired CFR has added value for predicting adverse outcomes. 
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Abbreviations 
CABG = coronary artery bypass grafting 
CAD = coronary artery disease 
CFR = coronary flow reserve 
MACE = major adverse cardiac advents 
MBF = myocardial blood flow 
MPI = myocardial perfusion imaging 
PCI = percutaneous coronary intervention 
PET = perfusion emission tomography 
SPECT = single photon emission computerized tomography 
SSS = summed stress score 
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Introduction:  
A large body of literature has established evidence that myocardial perfusion imaging 
(MPI) with single photon emission computerized tomography (SPECT) not only allows 
accurate detection of coronary artery disease (CAD) but also reliably discriminates 
between patients at low versus those at high risk of major adverse cardiovascular 
events (MACE) including cardiac death [1]. A normal SPECT MPI may reliably 
exclude an adverse outcome even in the present of coronary lesions. This has 
recently been extended to MPI with PET and 82Rb [2], although data on head-to-head 
comparison in large trials is missing. PET has been reported to confer increased 
accuracy over SPECT [3-5]. The superiority of PET has been attributed to technical 
characteristics such as higher photon energy, improved resolution, and intrinsic 
attenuation correction. The latter has enabled PET to emerge as an unique technique 
for non-invasive assessment of absolute quantitative myocardial blood flow (MBF), 
from which coronary flow reserve (CFR) can be calculated [6]. CFR has been 
proposed as an index to evaluate the coronary circulation in the epicardial coronary 
arteries and the microcirculation. 
Outcome data on PET MPI is scarce, and outcome data on CFR is limited to 
subgroups of patients such as those with non-ischemic dilative [7] or hypertrophic 
cardiomyopathy [8]. The aim of the present study was to evaluate the long-term 
prognostic value 13N-ammonia PET and the potential added value of CFR in an 
unselected population of patients with suspected myocardial ischemia. 
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Material and Methods 
Patient population 
This retrospective study included 256 patients who underwent PET imaging 
because of suspicion of impaired myocardial perfusion, of which 150 patients had a 
known CAD. Follow-up was accomplished by obtaining a structured interview and a 
clinical history. Cardiovascular risk factors such as hypertension, 
hypercholesterolemia, smoking, diabetes mellitus or positive family history for CAD 
were assessed at the time of PET imaging by reviewing patient charts. Written 
informed consent was waived by the institutional review board. The protocol was 
reviewed by the local research ethics boards, the need for written informed consent 
was waived and verbal consent on the telephone was obtained. 
 
PET 
13N-ammonia PET was assessed in a one-day protocol at rest and during adenosine 
stress at standard rate (0.14 mg/min/kg) over 7 minutes as previously reported [9]. All 
patients received a 700 to 900 MBq injection of 13N-ammonia into a peripheral vein 
during 10 s as a slow bolus. Images were acquired in 2D mode either on a GE 
Advance PET scanner or on a discovery (LS/RX) PET/CT scanner (both GE 
Healthcare, Milwaukee, Wisconsin, USA) with a field of view between 14.6 and 15.7 
cm. The optimal imaging position was determined on a CT scout scan or a 2-min 
short transmission scan with an external 68Ge source. Dynamic acquisition of the 
emission scans were performed using a standard protocol consisting of 9 x 10-
second, 6 x 15-second, 3 x 20-second and 1 x 900-second frames. Transmission 
scan for photon attenuation correction was performed with an external 68Ge source or 
low dose CT attenuation correction (non-gated; 140 kV; 120-150 mA; and slice 
thickness: 3.75-4.75 mm) [10]. Images were reconstructed using filtered back 
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projection and for review the images were re-sliced in short-axis as well as in vertical 
and horizontal long-axis orientation. 
 
Data analysis 
Regional 13N-ammonia uptake was assessed using the 17-segment model and the 
semiquantitative scoring system of defect severity and extent as recommended by the 
American Society of Nuclear Cardiology [11]. A scan was considered normal if the 
summed stress score (SSS) was <4, mildly abnormal if SSS was between 4 and 8, 
moderately / severely abnormal if SSS was >8 as previously reported in PET studies 
[2]. Image interpretation according to these definitions was performed by two 
experienced readers. Diverging interpretations were classified by consensus. 
Quantitative MBF was determined using the PMOD software package (Version 2.1-
2.8, PMOD Technologies Ltd.) developed and validated at our institution [12,13]. 
Therefore, a spherical ROI was placed into the blood pool of the left ventricle. 
Myocardial and blood pool time-activity curves were generated from the dynamic 
frames and corrected for radioisotope decay. MBF was estimated by model fitting of 
the blood pool and myocardial time-activity curves [14] correcting for partial volume 
and spillover as previously described [15]. CFR was calculated as the ratio of 
hyperemic to resting MBF, and CFR ≥ 2.0 was considered normal [16]. The CFR 
values of the 17-segments were assigned to the three coronary territories according 
for Cerqueira [17]. Territories with perfusion defects were assumed to be subtended 
by coronary vessels with CAD, while the other segments were classified as remote. 
Mean regional CFR was assessed for CAD and remote segments.  
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Long-term follow-up 
Patients` follow-up was obtained by use of a questionnaire that was assessed by a 
phone call to all the patients and/or general practitioners or cardiologists. If 
unsuccessful an identical written questionnaire was sent. Additional information was 
gathered by use of medical charts and the registry of government authorities in case 
of death. The mean follow-up was 5.5 ± 2.1 years. End points were defined as 
cardiac death or MACE including cardiac death (as declared in the medical charts), 
non-fatal myocardial infarction [18], hospitalization due to any cardiac reasons 
including late percutaneous coronary intervention (PCI) or late coronary artery bypass 
grafting (CABG). CABG and PCI within 60 days from PET scan were considered to 
be triggered by the scan and therefore excluded from further analysis. The date of the 
last examination of consultation was used to determine follow-up.  
 
Statistical analysis 
Continuous data were expressed as mean ± SD. Differences in survival over time 
were analyzed by the method of Kaplan-Meier. The log-rank test was used to 
compare the survival curves. Univariate and multivariate Cox proportional hazard 
regression models were used to identify independent predictors of cardiac events. 
Variables were selected in a stepwise forward selection manner; where entry and 
retention sets with a P < 0.05 were considered to indicate a significant difference The 
variables included in the models were age, male gender, hypertension, 
hypercholesterolemia, smoking, diabetes mellitus, a positive family history for CAD, 
abnormal perfusion and an impaired CFR (< 2.0). A variable’s risk was expressed as 
hazard ratio with corresponding 95 % CI. A P-value of less than 0.05 was considered 
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as significant. All statistical analysis was conducted using SPSS software (SPSS 
15.0, Chicago, IL, USA).  
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Results 
Patient characteristics 
13N-ammonia PET was performed in 256 patients. Follow-up was successful in 245 
(96%) patient. Of these, 16 patients were excluded due to early revascularization (< 
60 days). Baseline characteristics of the remaining 229 patients in the final analysis 
are given in table 1.  
 
Perfusion findings and CFR 
13N-ammonia uptake was normal in 103 patients and abnormal in 126 patients. The 
detailed distribution of patients with normal or reduced CFR in relation to perfusion 
findings is given in table 2. In 109 of 126 patients with abnormal perfusion regional 
CFR values were available. CFR was significantly lower in the defect zone (1.8 ± 0.7) 
than in remote territories (2.3 ± 0.9; p < 0.001). 
 
Outcome data 
During 5.5 ± 2.1 years follow-up cardiac death occurred in 29 patients and 
hospitalizations due to any cardiac reason in 47 including CABG in 14, and 30 with 
late PCI and non-fatal myocardial infarction. The Kaplan-Meier survival curves 
indicated that patients with an abnormal PET perfusion had a significantly higher rate 
of MACE (P < 0.001) and cardiac death (P < 0.05) compared to those with normal 
perfusion (Fig. 1A). Similarly, patients with abnormal CFR had a significantly higher 
rate of MACE (P < 0.001) and cardiac death (P < 0.05) than those with normal CFR 
(Fig. 1B). The predictive value of both, perfusion and CFR findings proved to be 
significant (p < 0.001 and p < 0.05) by Cox regression analysis and were confirmed to 
be non-interacting predictors by the interaction test. 
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In addition, by multivariate analysis CFR and perfusion were independently 
associated with MACE (CFR: P < 0.05; Perfusion: P < 0.001). CFR was also 
independently associated with death (P < 0.05), while this analysis fell short of 
statistical significance for perfusion defect (P = 0.05) (Table 3). Moreover, Chi-square 
values significantly improved when CFR is added to the multivariate analysis (MACE: 
P < 0.05, cardiac death: P < 0.01). In patients with abnormal perfusion CFR allows 
further stratification of cardiac risk throughout the full follow-up of 10 years (Fig 2A). 
The added predictive value of CFR for MACE (P < 0.05) and cardiac death (P < 0.05) 
is preserved even if the abnormal perfusion group is further subdivided into mild and 
moderate to severe defects. In patients with normal perfusion CFR does not allow to 
predict events throughout the full 10-year period of observation (Fig. 2B), as the 
survival curves start to converge after the third follow-up year resulting in an average 
annual rate of 1.7 % / year for MACE and 0.07 % for cardiac death. For the first 3 
years, however, pathologic CFR was associated with a significantly higher annual 
event rate for MACE (6.25 versus 1.4 %/year; P < 0.05) and cardiac death (3.1 
versus 0.5 %/year; P < 0.05) compared to normal CFR (Fig. 3).  
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Discussion 
The advantage of PET over SPECT has been often attributed to the ability of PET to 
assess CFR. However, no data exist on outcome in an unselected population group, 
although CFR has been reported to be inversely correlated to the Framingham risk 
score [19]. Our results demonstrate an added prognostic predictive value of CFR over 
perfusion findings alone as CFR was an independent predictor of adverse outcome. 
In fact, in patients with normal perfusion an abnormal CFR allowed further 
discrimination of patients with high from those with low annual event rate. This 
predictive value was maintained over up to 3 years of follow-up, while the survival 
curves converged during the following years. This may suggest a “warranty” period of 
about 3 years for a normal perfusion associated with a normal CFR by 13N-ammonia 
PET, while a normal CFR in patients with normal perfusion cannot predict long-term 
disease onset. However, patients with normal perfusion and impaired CFR seem to 
be at increased risk for cardiac events and death. In these patients CFR is most 
probably reflecting coronary endothelial and microcirculatory dysfunction while 
relevant epicardial coronary obstructive disease is unlikely. In fact, in the past two 
decades a number of studies have reported that abnormalities in the function and 
structure of the coronary microcirculation occur in many clinical conditions. In some 
cases dysfunction of the coronary microcirculation may be an indicator of early 
atherosclerosis preceding overt CAD [16]. Therefore, coronary microvascular 
dysfunction in the absence of obstructive CAD has been described as functional 
counterpart of traditional coronary risk factors. Since this type of dysfunction is at least 
partly reversible, its assessment might be used to guide interventions aimed at 
reducing the burden of risk factors [16]. Similarly a recent study has found an 
increased calcium score as predictor of adverse outcome in patients with normal MPI 
PET using 82Rb [20]. This supports our findings, as an increased calcium score has 
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been associated with coronary endothelial dysfunction [21]. Invasively assessed 
coronary endothelial dysfunction has also been associated with adverse outcome in 
patients with cardiovascular risk factors [22]. Our study extends this observation to an 
unselected patient population by non-invasive assessment of CFR which allows its 
clinical application in clinical routine. As CFR can be repeatedly assessed due to its 
non-invasive nature, it has been suggested as a tool for monitoring effects of risk 
factor modification such as for example lipid lowering treatment [23]. Whether this, 
however, translates into risk modification and prognostic benefit remains to be 
elucidated.  
Interestingly, in patients with overt ischemia as evidenced by abnormal PET 
perfusion, CFR is a strong prognostic predictor. By contrast to the finding in normal 
perfusion, this predictive value was maintained to the end of follow-up. It appears that 
CFR is a strong predictor of disease progression once disease is present. This may 
be due to the fact that impaired CFR may indicate extension of the disease beyond 
the epicardial coronary arteries down to the microcirculation representing a more 
advanced disease stage which is, thus, more prone to deterioration.  
A limitation of the present study may be the use of global but not regional CFR, 
because in the global value the regional findings may be diluted. Although CFR was 
lower in CAD segments the effect of dilution may be counterbalanced by the fact that 
CFR may be also impaired in remote segments of CAD patients, which is in line with 
previous reports [24]. In addition, global CFR values represent an integration of both 
extent and severity of perfusion defects, as a small defect with very low CFR and a 
larger defect with slightly decreased CFR will result in the same reduction in CFR, 
appropriately indicating the same risk. This may explain why global CFR proved an 
independent predictor of risk in our study and is in line with the concept of SSS as a 
global risk predictor according to the American Society of Nuclear Cardiology [11]. 
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However, the global CFR seems to be most appropriate to include the aspect of 
microcirculatory dysfunction without or on top of epicardial disease. Furthermore, for 
reasons of practicability the use of global CFR seems preferable over regional CFR 
values as the repeatability and the reproducibility of global CFR is substantially 
superior to that of regional CFR [25,26]. 
The retrospective nature of this study and the limited number of patients particularly in 
the subgroup with normal perfusion and impaired CFR may represent a limitation. 
Therefore, larger prospective studies to further support the prognostic value of 
quantitative PET imaging are needed. Furthermore, the Kaplan-Meier survival curves 
are not risk-adjusted. However, the independent added value of CFR in predicting 
outcome was documented by multivariate COX analysis. Finally, it could be perceived 
as a weakness of our study that we included an unselected patient population with 
and without CAD and/or other myocardial diseases. However, the aim of the present 
study was to evaluate the added value of CFR in a general patient group referred to 
PET, which allows the non-invasive assessment of CFR. Nevertheless, the annual 
event rate for MACE (1.7%) and for cardiac death (0.7%) for the total 10 year period 
in patients with normal perfusion ranges well within the previously reported values of 
1.6%-1.8% for MACE [2,27,28] in normal SPECT and PET and 0.9% for cardiac 
death [29], confirming that the present study has included a representative patient 
population.  
In conclusion, perfusion findings in 13N-ammonia PET and CFR are strong outcome 
predictors. CFR allows further risk stratification, suggesting a “warranty” period of 3 
years if associated with normal perfusion. Conversely, in patients with abnormal 
perfusion, an impaired CFR has added value for predicting adverse outcomes. 
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Figure legends: 
Figure 1: Kaplan-Meyer survival curves (unadjusted) for the entire study population  
A) Perfusion findings predict major adverse cardiac events (MACE, left panel) and 
cardiac death (right panel) in the entire study population. 
B) Coronary flow reserve (CFR) predicts MACE (left panel) and cardiac death (right 
panel) in the entire study population. 
Figure 2: Kaplan-Meyer survival curves (unadjusted) showing prognostic value of 
coronary flow reserve (CFR) in patients with abnormal versus normal perfusion.  
A) CFR predicts major adverse cardiac events (MACE, left panel) and cardiac death 
(right panel) in patients with abnormal perfusion findings. 
B) The prognostic value of CFR to predict MACE (left panel) and cardiac death (right 
panel) in patients with normal perfusion is confirmed to the first 3 years, while the 
survival curves merge throughout the subsequent years of follow-up. 
Figure 3: Kaplan-Meyer survival curves (unadjusted) showing added value of 
coronary flow reserve (CFR) in predicting outcome up to 3 years. Abnormal CFR 
predicts adverse outcome, i.e. major adverse cardiac events (MACE; A) and cardiac 
death (B) despite normal perfusion. This is reflected by the higher annual event rate 
(%/year) in abnormal CFR (C).  
 
 
 



 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean ± SD or number (%) of patients. 
PCI = Percutaneous coronary intervention; CABG =  
Coronary artery bypass grafting; CCS = Canadian  
Cardiovascular Society; NYHA = New York Heart Association. 
 
Table 1. Baseline Characteristics 
  n = 229 
Age (Years)  60 ± 12   
Male     69% 
Female     31% 
Hypertension     60% 
Hypercholesterolemia     59% 
Diabetes mellitus     18% 
Smoking     42% 
Positive family history     36% 
Coronary artery disease     66% 
Prior revascularization 
   PCI 
   CABG 
 
    29% 
    24% 
Angina symptoms (CCS class ≥ 2)     62% 
Dyspnea (NYHA functional class ≥ II)     24% 
Medication 
  Platelet aggregation inhibitor 
  Anti-ischemic agents 
  Lipid lowering agents 
 
    91% 
    82% 
    66% 
Table 2. Incidence of MACE and Cardiac Death (10-year follow-up) 
A            Separate Predictive Value of Perfusion and CFR  
 Perfusion  CFR 
 Normal (n=103) Abnormal (n=126) P  Normal (n=127) Abnormal (n=102) P 
MACE (n=76) 17 (16.5%) 59 (46.8%) <0.001  30 (23.6%) 46 (45.1%) <0.001 
Cardiac Death (n=29) 7 (6.8%) 22 (17.5%) <0.05  8 (6.3%) 21 (20.6%) <0.05 
 
 
B             Added Value of CFR Combined with Perfusion 
 Perfusion Normal  Perfusion Abnormal 
 CFR Normal (n=71) 
CFR  
Abnormal (n=32) P 
 CFR 
Normal (n=56) 
CFR 
Abnormal (n=70) P 
MACE (n=76) 10 (14.1%) 7 (21.9%) NS  20 (35.7%) 39 (55.7%) <0.05 
Cardiac Death (n=29) 4 (5.6%) 3 (9.4%) NS  4 (7.1%) 18 (25.7%) <0.05 
CFR = Coronary flow reserve; MACE = Major adverse cardiac events, NS = Non significant 
P values indicate results from log rank test. 
 
CFR = Coronary flow reserve; NS = Non significant; NA = not applicable 
 
 
 
 
 
Table 3. Predictors of Events at Univariate and Multivariate Analysis 
 Major adverse cardiac events 
 
Cardiac death 
Predictors Univariate P Multivariate P 
 
Univariate P Multivariate P 
Age 1.04 (1.02-1.06)  <0.001 1.03 (1.01-1.05) <0.01  1.06 (1.02-1.10) <0.01 1.05 (1.01-1.09) <0.01 
Male 2.90 (1.52-5.44)  <0.001 NA NS  1.99 (0.76-5.23)   NS NA NS 
Hypertension 1.28 (0.80-2.04)    NS NA NS  0.98 (0.47-2.05)   NS NA NS 
Hypercholesterolemia 1.23 (0.77-1.96)    NS NA NS  0.93 (0.44-1.95)   NS NA NS 
Diabetes mellitus 1.80 (1.07-3.01)  <0.05 1.94 (1.14-2.87) <0.05  0.74 (0.47-2.86)   NS NA NS 
Smoking 1.78 (1.14-2.79)  <0.05 1.78 (1.10-2.87) <0.05  2.24 (1.06-4.76)   NS 2.40 (1.13-5.11) <0.05 
Positive family history 1.13 (0.71-1.80)    NS NA     NS  0.70 (0.31-1.57)   NS NA NS 
Abnormal Perfusion 3.46 (2.02-5.94)  <0.001 2.58 (1.48-4.49)  <0.001  2.68 (1.14-6.27) <0.05 NA   0.05 
Impaired CFR 2.14 (1.35-3.37  <0.001 1,60 (1.00-2.57)   <0.05  3.53 (1.56-7.97) <0.01 2.86 (1.24-6.59) <0.05 
